Early and reliable detection of diseases is the basis for a healthy and long life.
protexam is based on the research of the mosaiques Group, which was founded in Hanover in 2002. The aim of the group is biotechnological research at the highest scientific and clinical level for the benefit of its customers. It is the international market leader in the field of clinical proteome analysis. The company's research and product development stands for the implementation of clinical proteome analysis in practice, the basis of personalised medicine. Mosaiques co-operates with numerous renowned clinics and institutes worldwide. The researcher Prof. Dr. Dr. Harald Mischak is the founder of the company and a member of the Management Board.
20
_____________________________
years of research
400
_____________________________
scientific publications
100
_____________________________
clinical studies
Milestones from 20 years of research
Serviceliste
-
2002Listenelement 1This year the coupling of capillary electrophoresis with mass spectrometry has been achieved. The mosaiques group is founded.
-
2003Listenelement 2It is shown for the first time that the determination of proteins and peptides in human urine using capillary electrophoresis mass spectrometry is a suitable tool for establishing new diagnostic markers.
-
2005A scientific study is published showing the high stability advantage of urine over blood plasma. Mosaiques applies statistical methods and artificial intelligence to read and process the relevant information from the multidimensional proteome data.
-
2006Through further research, the first disease markers for prostate cancer and bladder cancer are being discovered.
-
2008The first positive study results for the early detection of heart disease and kidney disease are published.
-
2009Initial study results suggest an association between age and kidney disease.
-
2010Recommendations and guidelines for the identification and qualification of biomarkers in clinical proteome analysis are defined and published.
-
2012The validity of clinical proteome analysis is established in the context of heart failure.
-
2014The world's first proteome-driven randomized multicenter clinical intervention trial is launched.
-
2016The American Food and Drug Administration (FDA) appoints Prof. Dr. Harald Mischak issued a “letter of support” to use clinical proteome analysis in pharmaceutical studies.
-
2017Another breakthrough is achieved: With the help of proteome analysis, a distinction can be made between different kidney diseases.
-
2018Proteome analysis can be used to detect a predisposition to cancer at an early stage.
-
2020The first prospective intervention study is published in which therapy was initiated through the early detection of diabetic kidney disease using clinical proteome analysis.
-
2021Biological age can be determined using clinical proteome analysis and the dynamics of aging can be predicted.
-
2022The prospective multicenter cohort study on the predictive performance and clinical application of the test for the early detection of severe COVID-19 disease was successfully completed.
-
2023
A method for prognosis and personalized in-silico prediction of treatment effectiveness in cardiovascular and chronic kidney diseases was developed.